Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Other Working Capital Changes (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 16 years of Other Working Capital Changes data on record, last reported at $5.5 million in Q4 2025.

  • For Q4 2025, Other Working Capital Changes rose 323.76% year-over-year to $5.5 million; the TTM value through Dec 2025 reached -$46000.0, up 99.4%, while the annual FY2025 figure was -$46000.0, 99.4% up from the prior year.
  • Other Working Capital Changes reached $5.5 million in Q4 2025 per LCTX's latest filing, up from -$1.8 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $5.5 million in Q4 2025 and bottomed at -$11.0 million in Q3 2022.
  • Average Other Working Capital Changes over 5 years is -$1.2 million, with a median of -$1.3 million recorded in 2025.
  • Peak YoY movement for Other Working Capital Changes: crashed 5556.98% in 2022, then soared 323.76% in 2025.
  • A 5-year view of Other Working Capital Changes shows it stood at -$86000.0 in 2021, then tumbled by 1950.0% to -$1.8 million in 2022, then soared by 126.89% to $474000.0 in 2023, then tumbled by 623.0% to -$2.5 million in 2024, then skyrocketed by 323.76% to $5.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Working Capital Changes were $5.5 million in Q4 2025, -$1.8 million in Q3 2025, and -$2.5 million in Q2 2025.